The discovery of activating epidermal growth factor receptor (EGFR) mutations, which respond to EGFR tyrosine kinase inhibitors (TKIs), was initially made in Asian women and non-smokers with lung adenocarcinoma (3–5). This evidence concerns the gene EGFR and lung adenocarcinoma.